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INTRODUCTION
Peripheral T-cell lymphomas (PTCL) are relatively rare in
Western countries, and account for only 10 to 15% of all
non-Hodgkin’s lymphomas (NHL’s) (1, 2). Compared with
Western countries, regions in Asia such as Hong Kong, Japan,
and China have higher rates of PTCL (3). In Korea, PTCL
constitute approximately 25 to 35% of all NHL’s (4, 5). PTCL
consist of a variety of uncommon and rare entities. One of
the predominantly nodal PTCL, anaplastic large cell lym-
phoma (ALCL) is heterogeneous in nature in terms of its clin-
ical, morphologic, and cytogenetic features. Clinically, ALCL
can be subdivided into primary (systemic and cutaneous) and
secondary (anaplastic transformation from another lymphoma)
forms, and primary systemic ALCL accounts for about 5% of
all NHL’s in adults (2, 6). ALCL was found to be associated
with the t(2;5) translocation (7), which results in the expres-
sion of anaplastic lymphoma kinase (ALK) protein. Moreover,
there is an increasing evidence that the clinical features and
the outcome of systemic ALCL are significantly dependent
on ALK expression (8, 9). The heterogeneity of the clinical
features and outcomes of ALCL in different studies is proba-
bly due to differences in diagnostic criteria and age distribu-
tions, and to the inclusion (in addition to cases of systemic
ALK-positive ALCL) of a variety of unrelated entities with a
different prognosis, such as primary cutaneous ALCL and
ALK-negative systemic ALCL. 
Despite recent advances in the characterization of ALCL,
its clinical outcome and optimal treatment have not clearly
determined. In Korea, ALCL constitutes approximately 1.5
to 1.9% of NHL (4, 5). We report here upon Korean expe-
rience concerning the clinical characteristics and treatment
outcome of ALCL patients at a single institution. 
MATERIALS AND METHODS 
Patient population
The medical records of 32 consecutive adult patients with
ALCL CD30+ (Ki-1), older than 16 yr were reviewed. All
patients had been newly diagnosed between March 1993 and
May 2003 at the Seoul National University Hospital. Histo-
pathologic material was reviewed by one pathologist. A diag-
nosis of ALCL was made according to the standard diagnos-
tic criteria detailed in the World Health Organization (WHO)
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Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean
Institution: Clinical Characteristics and Treatment Outcome
Despite advances in the characterization of anaplastic large cell lymphoma (ALCL),
little data is available on Asian patients. We report here upon single Korean institu-
tion’s experience regarding the clinical characteristics and outcomes of ALCL. We
performed a retrospective study of 32 adults with ALCL. Most of the patients received
anthracycline-based chemotherapy. Ann Arbor stage III-IV, B symptoms, high-inter-
mediate/high International Prognostic Index (IPI), and extranodal disease at diagno-
sis were present in 56%, 44%, 41%, and 63%, respectively. Compared with Western
studies, the male/female ratio (4.3) was markedly higher and skin (9%) and bone
involvement (9%) were less frequent. The staining results for anaplastic lymphoma
kinase were positive in 6 (33%) of 18 cases available. The complete response (CR)
rate was 62% (95% CI, 44-80%). With a median follow-up of 51.0 months, 5 yr overall
survival was 40±11%. The 3 yr relapse-free survival for the 18 patients who achieved
CR was 74±12%. Age, performance status, lactate dehydrogenase, extranodal
disease sites number, and IPI were correlated with treatment response and survival.
Our data suggest that Korean ALCL patients appear to have a higher male/female
ratio, less frequent skin/bone involvement, and lower CR rate compared with those
of Western studies. 
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classification for NHL (10), which includes classic histologic
features and tumor cell CD30 reactivity. The panel of mono-
clonal antibodies used included CD45, CD30, CD15, CD20,
CD79a, CD3, CD45RO, epithelial membrane antigen, Ki-
67, CD56, and CD68. 
Staging
Staging procedures included a physical examination, chest
radiography, abdominal computerized tomography (CT) scan,
a complete blood count, bilateral bone marrow aspirates and
biopsies, liver and renal function tests, and lactate dehydro-
genase (LDH) determinations. Staging was performed accord-
ing to the Ann Arbor staging systems for Hodgkin’s disease
(11). 
Treatment and assessment of response
Chemotherapy regimens consisted of CHOP (cyclophos-
phamide, doxorubicin, vincristine, prednisolone) (12), COP-
BLAM-V (vincristine, bleomycin, cyclophosphamide, dox-
orubicin, prednisolone, procarbazine) (13), CVP (cyclophos-
phamide, vincristine, prednisolone), BVP (bleomycin, vin-
cristine, prednisolone), IMEP (ifosfamide, methotrexate, eto-
poside, prednisolone), and CAPPE/VBM (cyclophosphamide,
doxorubicin, prednisolone, procarbazine, etoposide, vincristine,
bleomycin, methotrexate), and chemotherapy was adminis-
tered for a total of 6 cycles. One month after therapy com-
pletion, re-staging was performed by physical examination,
blood cell counts, liver and renal function tests, LDH evalu-
ation, CT scans of abdomen, chest radiography, and by bone
marrow biopsy, in cases showing tumor involvement at diag-
nosis. Assessment of treatment response was categorized as;
complete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD) according to the WHO
criteria (14). 
Statistical methods
Overall survival (OS) was measured from the date of diag-
nosis to the date of death from any cause or the date of the
last follow-up evaluation. Relapse-free survival (RFS) dura-
tion was calculated for CR patients from the date of CR until
documented relapse, death or the last follow-up date in remis-
sion. Survival rates were estimated using the Kaplan and Meier
method (15) and were compared using the log-rank test.
RESULTS
Patient characteristics
The main clinical findings of the 32 ALCL patients are
shown in Table 1. Twenty-six patients (81%) were male and
6 (19%) female. Median age was 51 yr (range, 16-80 yr).
Sixty-three percent of patients showed peripheral lymph node
involvement. Advanced disease stage (Ann Arbor stage III-
IV), B symptoms, and extranodal disease at diagnosis were
present in 56%, 44%, and 63% of cases, respectively. The
frequencies of extranodal sites of lymphoma involvement were
as follows: liver (19%), lung (9%), pleural cavity (9%), peri-
toneal cavity (9%), skin (9%), and bone (9%), with involve-
ment of bone marrow (6%) or gut (6%) being uncommon.
The central nervous system (CNS) was affected in one patient
(3%). Patients in high-intermediate/high risk group (Interna-
tional Prognostic Index [IPI] 3-5) constituted 41% of the cases.
Immunohistochemistry showed CD30+in all cases. Pheno-
type was considered to be T-cell in 26 cases (81%) and null
in 6 cases (19%). Staining results for ALK were available in
18 cases and 6 cases (33%) were ALK positive. 
ECOG, Eastern Cooperative Oncology Group; IPI, International Prog-
nostic Index; ALK, anaplastic lymphoma kinase.
*Gut (2) and CNS (1), 
� Staining results for the ALK were available in 18
cases and 6 (33%) were ALK positive.
Characteristics No. %
Total 32 100
Gender
Male 26 81
Female 6 19
Age (yr)
Median (range) 51 (16-80)
ECOG Performance status
0-1 17 53
>1 15 47
B symptoms 14 44
Bulky disease 5 16
Lymphadenopathy 27 84
Peripheral 20 63
Intraabdominal 13 41
Mediastinal 4 13
Extranodal disease 20 63
Liver 6 19
Lung 3 9
Pleural cavity 3 9
Peritoneal cavity 3 9
Skin 3 9
Bone 3 9
Bone marrow 2 6
Others* 3 9
Ann Arbor stage
I-II 14 44
III-IV 18 56
LDH level
≤1× normal 13 41
>1× normal 17 53
IPI 
Low 13 40
Low-intermediate 6 19
High-intermediate 5 16
High 8 25
ALK
� 63 3
Table 1. Clinical characteristics of the patientsPrimary Systemic Anaplastic Large Cell Lymphoma 635
Response to treatment
Thirty of the 32 patients were treated with combination
chemotherapy: 15 (50%) with CHOP, 11 (37%) with COP-
BLAM-V, and 4 (13%) with other regimens (CVP, BVP,
CAPPE/VBM, IMEP). Twenty-nine patients were assessable
for response. After chemotherapy, the CR rate was 62% (18/
29; [95% confidence interval (CI), 44-80%]) and the PR rate
was 24% (7/29), with an overall response rate (CR+PR) of
86%; 14% (4/29) showed no response. Five out of 18 CR
patients after chemotherapy were treated by involved-field
radiation therapy due to initial bulky disease. 
Relapses
Four patients (22%) among 18 that achieved CR relapsed
between 2.9 and 36.2 months after chemotherapy completion
(median, 5.1 months) and a second remission was achieved
in 3 of these 4 by salvage chemotherapy, but the second remis-
sion duration was short (median, 2.6 months). Treatments for
relapses were rather heterogeneous: 3 patients received IMEP
and 1 patient DHAP (dexamethasone, cytarabine, predniso-
lone). 
Survival
At the time of this analysis, the median follow-up period
was 51.0 months (range, 11.6-135.9 months). The 5 yr OS
for all 30 patients that received chemotherapy was 40±11%
and the median OS was 54.0 months (95% CI, 0.8-107.2
months) (Fig. 1). The median OS for patients that achieved
CR had not been reached and the 5 yr survival rate was 78±
15%. In contrast, in patients who failed to achieve CR, medi-
an survival was only 7.0 months (95% CI, 2.1-11.9 months).
Median RFS for the 18 patients who achieved CR had not
been reached and the 3 yr RFS was 74±12% (Fig. 2). 
Prognostic factors for response and survival
Responses to chemotherapy by pretreatment characteris-
tics are detailed in Table 2. Age, performance status, LDH
level, extranodal disease sites number, and IPI were found
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Fig. 1. Overall survival of the 30 patients with ALCL who received
chemotherapy (median 54.0 months; 5 yr survival rate 40±11%).
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Fig. 2. Relapse-free survival for the 18 patients who achieved com-
plete remission (3 yr relapse-free survival rate 74±12%).
Variable Category
CR No.
(%)
p
Overall survival
Median
(months) 
(95% CI)
p
Age (yr) <60 14 (78) 0.02 NR  0.001
≥60 4 (36) 7.0 (0-30.1)
Performance ECOG 0-1 14 (82) 0.007 NR 0.002
status ECOG >1 4 (33) 7.0 (0-14.0)
B symptoms Absent 12 (80) 0.03 58.0 0.11
Present 6 (43) 9.0 (5.4-12.6)
Bulky disease Absent 16 (67) 0.26 54.0 (5.1-102.9) 0.49
Present 2 (40) 9.0 (0-21.9)
Extranodal 0-1 15  (75) 0.03 NR 0.02
disease site No. >1 3 (33) 17.0 (0-40.4)
Ann Arbor stage I-II 10 (77) 0.13 NR 0.14
III-IV 8 (50) 17.0 (5.2-28.8)
LDH level (IU/L) ≤400 16  (76) 0.008 NR 0.003
>400 1 (17) 7.0 (0-14.2)
IPI Low 11 (85) 0.02 NR 0.03
Low- 4 (80) NR
intermediate
High- 2 (40) 19 (0-40.5)
intermediate
High 1 (17) 3.0
ALK Absent 6 (55) 0.23 7.0 (0-53.7) 0.35
Present 5 (83) NR
Table 2. Prognostic factors influencing on complete remission
rates and overall survival 
CR, complete remission; NR, not reached; ECOG, Eastern Cooperative
Oncology Group; IPI, International Prognostic Index; ALK, anaplastic
lymphoma kinase.636 S.R. Park, J.Y. Baek, D.-W. Kim, et al.
to be correlated with treatment response and with survival
by univariate analysis. And, B symptoms were found to be
correlated with response to treatment. IPI, which was devel-
oped for aggressive lymphomas in general, predicted survival
in our group of patients (Fig. 3). The CR rates of the low, low-
intermediate, high-intermediate, and high IPI risk groups
were 85%, 80%, 40%, and 17% (p=0.02), respectively. Medi-
an OS was not reached in the low and low-intermediate IPI
risk group, but was 19.0 months and 3.0 months in the high-
intermediate and high risk group, respectively (p=0.03) (Table
2). When grouped into 2 categories (low/ low-intermediate
and high-intermediate/high IPI risk groups), the CR rates of
the low/low-intermediate and high-intermediate/high IPI risk
groups were 83% and 27%, respectively (p=0.005). Median
OS was not reached in the low/low-intermediate IPI risk group,
but was 9.0 months (95% CI, 0-24.1 months) in the high-
intermediate/high risk group (p=0.001).
Meanwhile, no significant differences were found between
the CR rate and survival of ALK-positive and ALK-negative
cases; The CR rates of ALK-positive and ALK-negative ALCL
cases were 83% and 55%, respectively (p=0.23) and their
respective 5 yr survival rates were 60% and 25% (p=0.39).
DISCUSSION
Current knowledge of ALCL is limited because of the small
numbers of patients analyzed in single series and the hetero-
geneity of treatments administered (16-21). Moreover, this
is the first report to describe the clinical features and treat-
ment outcomes of Korean ALCL patients. 
Our study confirms the male predominance in ALCL (male:
female, 26:6) and the young age of onset of ALK-positive
ALCL (median age, 17 yr), as reported by others (8). The
male/female ratio (4.3), however, was markedly higher than
those found in Western studies (1.4-1.8) (19, 20). ALCL
patients in this study usually presented with enlarged periph-
eral, abdominal, or mediastinal nodes (84%). Similarly to
other studies (16-20), ALCL patients in this study frequently
presented with advanced disease (stage III-IV) (56%), B symp-
toms (44%), extranodal disease at diagnosis (63%), and high-
intermediate or high risk IPI (41%). Extranodal sites were the
liver (19%), lung (9%), pleural cavity (9%), peritoneal cavity
(9%), skin (9%) and bone (9%). Bone marrow (6%), gut (6%),
and CNS (3%) involvement were uncommon events. It appears
that skin and bone involvement in our study are less frequent
than those found in Western studies (8, 16). However, the
small number of patients in our study prevents our drawing
firm conclusions in terms of clinical presentations. Most of
the clinical features except for gender ratio and extranodal
involvement pattern in Korean ALCL patients in the present
study are similar to those reported in the West (16-20) and
other Asian countries (22, 23), though there are few data in
Asians.
Despite recent advances in the characterization of ALCL,
its rarity has belied the establishment of an optimal treatment.
Although no large comparative studies have been published,
most investigators have reported that response to chemother-
apy is good, ranging from 60% to 90% in ALCL (16-21).
Most patients (90%) in the present study received anthracy-
cline-based chemotherapy regimens. CR rate was 62% (95%
CI, 44-80%), and the 5 yr OS for all 30 patients that received
chemotherapy was 40±11% and the median OS was 54.0
months. Three-year RFS of the 18 patients who achieved CR
was 74±12%. In the literature, OS and disease-free survival
for ALCL treated by chemotherapy ranges from 29% to 77%
and from 50% to 67%, respectively (16-21). Although the
outcomes in the present study may be less informative because
of various treatment regimens, the CR rate of 62% and 5 yr
survival rate of 40% was at the lower limit of what has been
reported in the West (16-21). 
There is now evidence that the clinical features and out-
comes of systemic ALCL differ significantly for cases harbor-
ing or lacking ALK expression (8, 9, 24). In our study, the
expression of ALK protein was confirmed retrospectively by
immunohistochemistry in 6 of 18 cases (33%) examined.
The ALK expression rate in our study appears to be lower
than the 50-60% reported in the literature (8, 9, 25), how-
ever, small number of cases makes it difficult to draw a firm
conclusion.
In the present study no significant differences were found
between the clinical features or survivals of ALK-positive
and ALK-negative cases, which is not surprising given the
small number of ALK cases available (n=18). ALK-positive
ALCL more frequently presented with aggressive stage III
to IV disease (50% vs. 33%), extranodal involvement (83%
vs. 42%), and low/low-intermediate IPI (83% vs. 58%),
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Fig. 3. Overall survival according to International Prognostic Index
in the 30 patients who received chemotherapy. The median survival
of low and low-intermediate group was not reached and that of
high-intermediate and high risk groups was 19.0 months and 3.0
months, respectively (p=0.03). and had high CR rate (83% vs. 55%) and 5 yr survival rate
(60% vs. 25%), but all were without statistical significance.
For further evaluation of the significance of ALK in Korean
ALCL patients, a larger national or multi-institutional study
is needed. 
In addition to ALK-positivity, IPI has been identified as
an important factor for predicting prognosis in ALCL by
several studies (9, 26, 27). In patients with ALK-positive
lymphomas, the 5 yr survival rate was 94±5% in the low-
to intermediate-risk group (age adjusted IPI: 0-1) and 41±
12% in the high- to intermediate-risk group (age adjusted
IPI: ≥2) (8). In cases of ALK-negative ALCL, IPI was also
found to be a significant prognostic factor of OS (28). Simi-
larly, in our study, IPI was correlated with treatment response
and survival by univariate analysis. High-intermediate/high
risk group had lower CR rate and shorter survival than low/
low-intermediate risk group. IPI may be more useful in ALK-
negative systemic ALCL in which the clinical outcome is
highly variable and more difficult to predict in individual
cases (26, 29).
ALCL patients have better survival than those with other
forms of PTCL (30, 31). However, this relatively favorable
prognosis of ALCL can be attributed to the subgroup with
ALK expression. ten Berge et al. (28) reported no differences
in overall and progression-free survival in ALK-negative ALCL
and PTCL-NOS (not otherwise specified). Therefore, future
treatment strategy in ALCL need to be stratified according
to known risk factors, such as, ALK-negativity and high/
high-intermediate IPI.
In conclusion, our data suggest that Korean ALCL patients
appear to have a higher male/female ratio, less frequent skin
and bone involvement, and lower CR rate to anthracycline-
based chemotherapy compared with those found in Western
studies. These, however, need to be further investigated in
larger national or multi-institutional study. Further treat-
ment study stratified according to risk factors such as ALK
expression and IPI would contribute to the establishment of
an optimal treatment for ALCL. 
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